Cancer diagnostics often begin with a biopsy and histopathologic examination, from the basis of physical examination and medical history. Sometimes the first indication is an abnormal laboratory test result (eg, anemia resulting from colon cancer).
-
DATE: January 30, 2020 TIME: 9:00am PST, 12:00pm EST Recent advances in in vitro 3D cellular culture technologies, such as organoids, rapidly developed and established novel, more physiologi...
Fecal elastase-1 – a biomarker for pancreatic exocrine insufficiency(EPI) continues to gain traction as an ideal biomarker for assessing EPI. This presentation will include a review of...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
The liver plays a critical role in the metabolism and clearance of more than 70% of marketed drugs. Furthermore, toxicity to the liver is a major reason for preclinical and clinical drug fai...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
Biomarkers are critical tools for all stages of cancer research, from drug development through clinical applications. Cancer is fundamentally a disease of unregulated cell growth and circumv...
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in developed countries, and it affects over 25% of the population worldwide. Within the next five y...